EspeRare CEO: Proceeds From Dermelix Co-Development Pact To Fund Genetic Pre-Natal Pipeline R&D
The CEO of Swiss not-for-profit foundation EspeRare tells Scrip how she will use funds generated from a co-development pact with Dermelix Biotherapeutics to create novel in utero treatments for rare genetic diseases.
You may also be interested in...
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.